Farnesyltransferase inhibitors versus Ras inhibitors

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 197-203

  Gibbs, Jackson B ^a   Graham, Samuel L ^a   Hartman, George D ^a   Koblan, Kenneth S ^a   Kohl, Nancy E ^a   Omer, Charles A ^a   Oliff, Allen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RODENTIA;

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; TRANSFERASE;

CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; ONCOGENE RAS; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; HUMANS;

EID: 0031197127     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80010-5     Document Type: Article

References (51)

1. Lowy DR, Willumsen BM: Function and regulation of Ras. Annu Rev Biochem 1993, 62:851-891.
2. Clark GJ, Der CJ: ras proto-oncogene activation in human malignancy. In Cellular Cancer Markers. Edited by Garrett CT, Sell S. Totowa, New Jersey: Humana Press, 1995:17-52.
3. Gibbs JB: Pharmacological probes of Ras function. Seminars Cancer Biol 1992, 3:383-390.
4. Buss JE, Marsters JC: Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chem Biol 1995, 2:787-791.
5. Der CJ, Cox AD, Sebti SM, Hamilton AD: Farnesyltransferase inhibitors: anti-Ras drugs for cancer treatment? Anti-Cancer Drugs 1996, 7:165-172.
6. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997, 37:143-166.
7. Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem 1996, 271:5289-5292.
8. Boyartchuk VL, Ashby MN, Rine J: Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 1997, 275:1796-1800. First molecular characterization of a CaaX protease. Genetic inhibition of the protease inhibited Ras function in yeast but was not toxic to the yeast. This work should lead to the cloning of mammalian CaaX protease, which is a potential target for the development of inhibitors with anti-Ras activity.
9. Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 1992, 61:355-386.
10. Dudler T, Gelb MH: Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes. J Biol Chem 1996, 271:11541-11547.
11. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997, 272:10608-10615. Biochemical and biological evidence that Rheb is a target of FPTase inhibitors. Rheb is farnesytated and the farnesylation is blocked by an FPTase inhibitor. Since this GTP-binding protein was found to inhibit Ras functions, alteration of Rheb activity might also affect Ras pathways.
12. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 1997, 272:15591-15594. Biochemical evidence that RhoB is a target of FPTase inhibitors. RhoB is both farnesylated and geranylgeranylated, and the results of this paper show that an FPTase inhibitor blocks RhoB farnesylation in cells. Since RhoB was previously shown to be required for Ras function, the results suggest that inhibition of RhoB farnesylation by FPTase inhibitors may be a mechanism by which these compounds exhibit an anti-proliferative effect.
13. Kohl NE, Wilson FR, Mosser SD, Guiliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J et al.: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 1994, 91:9141-9145.
14. Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa J-i, Yamazaki E, Ishiguro H, Matsuzawa Y: Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res 1996, 87:113-116.
15. ••]) confirm that Ki4B-Ras is normally farnesylated in cells. However, in cells treated with an FPTase inhibitor, Ki4B-Ras was found to be geranylgeranylated. This result provides chemical evidence which explains why Ki4B-Ras processing in cells is resistant to FPTase inhibitors.
16. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995, 55:5310-5314.
17. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995, 55:4243-4247.
18. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995, 55:5302-5309.
19. Zhang FL, Kirschmeier, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang RM, Bishop WR: Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997, 272:10232-10239.
20. Lerner EC, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995, 270:26770-26773.
21. V12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 1996, 93:4454-4458. Ki4B-Ras processing is resistant to FPTase inhibitors in cells. This result raised the possibility that FPTase inhibitors may not effectively inhibit the growth of Ki4B-ras transformed cells and that any inhibition observed might be due to inhibition of other farnesylated proteins that regulate cell proliferation.
22. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995, 270:6221-6226.
23. ••].
24. Sun J, Qian Y, Hamilton AD, Sebti SMH: Both farnesyltransferase and geranyleranyltransferase I inhibitors are required for disruption of K-Ras prenylation but each alone is sufficient for inhibition of human tumor growth [abstract]. Proc Am Assoc Cancer Res 1997, 38:352.
25. Lerner EC, Zhang TT, Qian Y, Hamilton AD, Sebti SM: Inhibition of K-Ras but not H- or N-Ras prenylation requires both farnesyltransferase and geranylgeranyltransferase I inhibitors in human tumor cell lines [abstract]. Proc Am Assoc Cancer Res 1997, 38:352.
26. Lebowitz PF, Davide JP, Prendergast GC: Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 1995, 15:6613-6622.
27. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ: Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995, 10:2289-2296.
28. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K et al.: Inhibition of farnesyltranserase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995, 1:792-797.
29. Lebowitz PF, Sakamuro D, Prendergast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997, 57:708-713. FPTase inhibitors can induce apoptosis. Previously, it was thought that FPTase inhibitors might only function as cytostatic agents. These new data suggest that FPTase inhibitors may cause tumor regression by a cell death mechanism.
30. Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE: Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res 1996, 56:2626-2632.
31. Sattler I, Tamanoi F: Prenylation of Ras and inhibitors of prenyltransferases. In Molecular Biology Intelligence Unit Series. Edited by Maruta H. Austin TX: RG Landes; 1996:95-137.
32. Graham SL, Williams TM: Inhibitors of protein farnesylation. Exp Opin Ther Patents 1996, 6:1295-1304.
33. Williams TM, Ciccarone TM, MacTough SC, Bock RL, Conner MW, Davide JP, Hamilton K, Koblan KS, Kohl NE, Kral AM et al.: 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. J Med Chem 1996, 39:1345-1348.
34. Qian Y, Vogt A, Sebti SM, Hamilton AD: Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors. J Med Chem 1996, 39:217-223.
35. Njoroge FG, Doll RJ, Vibulbhan B, Alvarez CS, Bishop WR, Petrin J, Kirschmeier P, Carruthers NI, Wong JK, Albanese MM et al.: Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase. Bioorg Med Chem 1997, 5:101-113.
36. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N, Manne V: Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 1996, 39:353-358.
37. Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Hodges JC, Shu T-Z, Scholten JD, Gowan RC, Sebolt- Leopold JS, Doherty AM: Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem 1997, 40:192-200.
38. Wallace A, Koblan KS, Hamilton K, Marquis-Omer DJ, Miller PJ, Mosser SD, Omer CA, Schaber MD, Cortese R, Oliff A et al.: Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library. J Biol Chem 1996, 271:31306-31311.
39. Park H-W, Boduluri SR, Moomaw JF, Casey PJ, Beese LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution. Science 1997, 275:1800-1804. First structural view of FPTase. The authors present the beautiful structure of the FPTase heterodimer and provide the first glimpse into the active site which is the target of FPTase inhibitors.
40. Huang C-C, Casey PJ, Fierke CA: Evidence for a catalytic role of zinc in protein farneysltransferase. J Biol Chem 1997, 272:20-23.
41. Zhang FL, Fu H-W, Casey PJ, Bishop WR: Substitution of cadmium for zinc in farnesyl: protein transferase alters its substrate specificity. Biochemistry 1996, 35:8166-1871.
42. Villar KD, Mitsuzawa H, Yang W, Sattler I, Tamanoi F: Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem 1997, 272:680-687.
43. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL: Interaction of the Transforming Growth Factor-βtype I receptor with tarnesyl-protein transferase-α. J Biol Chem 1995, 270:29628-29631.
44. Ventura F, Liu F, Doddy J, Massague J: Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha in yeast and mammalian cells. J Biol Chem 1996, 271:13931-13934.
45. Wang T, Danielson PD, Li B-Y, Shah PC, Kim SD, Donahoe PK: The p21-RAS farnesyltransferase alpha subunit in TGF-beta and activin signaling. Science 1996, 271:1120-1122.
46. Goalstone ML, Draznin B: Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes. J Biol Chem 1996, 271:27585-27589.
47. Taveras AG, Remiszewski SW, Doll RJ, Cesarez D, Huang EC, Kirschmeier P, Pramanik BN, Snow ME, Wang Y- S, de Rosario JD et al.: Ras oncoprotein inhibitors: the discovery of potent, Ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg Med Chem 1997, 5:125-133.
48. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995, 92:7686-7689.
49. Kumar CC, Prorock-Rogers C, Kelly J, Dong Z, Lin J- J, Armstrong L, Kung H-F, Weber MJ, Afonso A: SCH 51344 inhibits ras transformation by a novel mechanism. Cancer Res 1995, 55:5106-5117.
50. Kim HA, Ling B, Ratner N: Nf1-Deficient mouse schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol 1997, 17:862-872.
51. Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG: The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed Rat embryo fibroblasts. Cancer Res 1996, 56:1727-1730.